Amplification/Deletion Probe

Order Number
Package Size
100 µl (10 Tests)



XL CDKN2C/CKS1B consists of a green-labeled probe hybridizing to the CDKN2C (p18) gene region at 1p32.3 and an orange-labeled probe hybridizing to the CKS1B gene region at 1q21-22.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.

Need assistance or a quote?

Clinical Details

Multiple myeloma (MM) is a plasma cell malignancy characterized by very complex cytogenetic and molecular genetic aberrations. Hyperdiploid karyotypes are characterized mainly by trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, non-hyperdiploid karytoypes typically have translocations involving the IGH locus at 14q32. The most frequent deletions are 13q, 17p and 1p32.

Deletions of chromosome 1p have been described in 7-15% of cases of myeloma with inconsistent clinical consequences. CDKN2C at 1p32.3 has been identified in myeloma cell lines as the potential target of the deletion. Gain of 1q is one of the most recurrent chromosomal aberrations in MM. Amplification and overexpression of the CKS1B gene in chromosome band 1q21 has been associated with an aggressive clinical course in MM.

Clinical Applications

  • Multiple Myeloma and Plasma Cell Neoplasms (MM)
Need assistance or a quote?



XL CDKN2C/CKS1B hybridized to lymphocytes. Three normal interphases are shown.

Need assistance or a quote?

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and three orange (3O) signals, indicating a gain of the CKS1B locus.

Expected Pattern 3

Aberrant Cell (typical results):
One green (1G) and two orange (2O) signals, indicating a loss of the CDKN2C locus.

Need assistance or a quote?


  • Hanamura et al (2006) Blood 108:1724-1732
  • Leone et al (2008) Clin Cancer Res 14:6033-6041
  • Jian et al (2016) Medicine 95:1-7